A Global Phase 2 Study of ARX788 in HER2-positiveMetastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1 and/or T-DXd and/or Tucatinib-containing Regimens | NYU Langone Health

Go Back to All Clinical Trials

A Global Phase 2 Study of ARX788 in HER2-positiveMetastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1 and/or T-DXd and/or Tucatinib-containing Regimens

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Her2-positive Metastatic Breast Cancer Patients Whose Disease Is Resistant Or Refractory To T-dm1, And/or T-dxd, And/or Tucatinib-containing Regimens
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Life expectancy > 3 months. 2) Eastern Cooperative Oncology Group Performance Status = 1. 3) Subjects must have been treated with trastuzumab plus taxane. Subjects who received prior pertuzumab, lapatinib, neratinib, margetuximab, and/or other available and accessible HER2-directed therapies or investigational therapies are eligible.

You may not be eligible for this study if the following are true:

1) History of allergic reactions to any component of ARX788. 2) Prior history of interstitial lung disease, pneumonitis, or other clinically significant lung disease within 12 months prior to screening with the exception of directly attributable to the presence of lung metastases from their underlying cancer. 3) Subjects with significant treatment related lung injury.